Navigation Links
Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)

NEW BRUNSWICK, N.J., May 2, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Friday, May 3, at approximately 8:30 a.m., Eastern Time, to discuss simeprevir phase 3 clinical data presented at The International Liver Congress of the European Association for the Study of the Liver (EASL).

A pre-recorded webcast featuring management from Janssen will provide an overview of results from the phase 3 QUEST -1 and QUEST-2 studies of the investigational protease inhibitor simeprevir (TMC435) administered once daily in combination with pegylated interferon and ribavirin in treatment-naive genotype 1 chronic hepatitis C patients.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at and clicking on "Webcasts/Presentations."



SOURCE Johnson & Johnson
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
2. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
3. Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
4. Janssen Pharmaceutica, NV, Funds New Global Mental Health Scholarships as Part of Its Healthy Minds Program
5. Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create Integrated Approaches to Healthcare Innovation in Newly Published Article
6. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
7. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
8. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
9. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
10. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
11. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
Post Your Comments:
(Date:11/30/2015)... YORK , Nov. 30, 2015 Cumberland Pharmaceuticals ... will present live at on December 3, 2015. ... --> TIME: 3:15p.m. ET LINK: ... ET LINK: --> ... online event where investors are invited to ask the company ...
(Date:11/30/2015)... Nov. 30, 2015 Varian Medical Systems (NYSE: VAR ... educational partnership with Apollo Hospitals Group, the largest hospital chain in ... help train radiation technologists in the country. The MoU was signed ... Knowledge, and Ashok Kakkar , Varian,s India ... India , Varian intends to deploy its Access ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... by UPMC and KingMed Diagnostics researchers. Their review of ... that consultation with UPMC pathologists resulted in significantly altered treatment plans for more ...
(Date:11/30/2015)... ... 30, 2015 , ... ”Dying Words: The AIDS Reporting of Jeff Schmalz and ... to coincide with World AIDS Day. The multi-media project will be in audio documentary ... as he was dying of the disease. , A collaborative effort led by author, ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... promoting breast and prostate cancer education and prevention—is joining forces with the award-winning ... philanthropy and Hollywood elegance on December 7, 2015 at the Union League of ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their exclusive channel partner for the Nutraceutical Specialties products into oral solid dosage ... effective immediately. , “We are pleased to announce our expanded distribution agreement ...
(Date:11/30/2015)... ... November 30, 2015 , ... California-based i2i ... years, announced today that Michigan-based Family Health Center (FHC) has selected i2iTracks as ... years, FHC was awarded the largest Affordable Care Act grant for Federally Qualified ...
Breaking Medicine News(10 mins):